ODAC meeting Part 1: FDA’s advisors unconvinced of ctDNA strategy for metastatic breast cancer

By Amanda Conti

The FDA’s Oncologic Drugs Advisory Committee voted against the demonstrated benefit of AstraZeneca’s camizestrant for a subset of metastatic breast cancer patients, casting doubt on a novel treatment strategy driven by circulating tumor DNA (ctDNA) monitoring.

The meeting centered on whether detecting resistance-associated mutations through ctDNA before radiographic progression should justify switching therapies — an approach the committee viewed as scientifically promising but insufficiently supported by current clinical evidence.

This AgencyIQ analysis examines the regulatory and scientific debates that shaped the ODAC discussion and what they could mean for future FDA policy on ctDNA-guided oncology development.

Fill out the form to read the full analysis.